Search results for "coronavirus"

showing 10 items of 1281 documents

Potential Influence of Helminth Molecules on COVID-19 Pathology

2020

In recent months, the parasitology research community has been tasked with investigation of the influence of parasite coinfection on coronavirus disease 2019 (COVID-19) outcomes. Herein, we share our approach to analyze the effect of the trematode Fasciola hepatica as a modulator of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and of COVID-19 pathology.

0301 basic medicinePathologymedicine.medical_specialtyFascioliasisCoronavirus disease 2019 (COVID-19)Helminth proteinSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)viruses030231 tropical medicineInfection modulation03 medical and health sciences0302 clinical medicineAntigenic ModulationPathology modulationparasitic diseasesMedicineParasite hostingFasciola hepaticaHelminthsAnimalsHumansImmunologic FactorsInflammationHelminth parasitesRespiratory Distress SyndromebiologyForumbusiness.industryCoinfectionvirus diseasesCOVID-19Helminth ProteinsFasciola hepaticamedicine.diseasebiology.organism_classificationImmunity Innate030104 developmental biologyInfectious DiseasesParasitologyCoinfectionParasitologybusinessTrends in Parasitology
researchProduct

Impact of COVID-19 on global HCV elimination efforts.

2021

Background & Aims COVID-19 has placed significant strain on national healthcare systems at a critical moment in the context of hepatitis elimination. Mathematical models can be used to evaluate the possible impact of programmatic delays on hepatitis disease burden. The objective of this analysis was to evaluate the incremental change in hepatitis C liver-related deaths and liver cancer, following a 3-month, 6-month, or 1-year hiatus in hepatitis elimination program progress. Methods Previously developed models were adapted for 110 countries to include a status quo or “no delay” scenario and a “1-year delay” scenario assuming significant disruption in interventions (screening, diagnosis and …

0301 basic medicinePsychological interventioncoronavirusUMIC upper-middle income countriesGlobal HealthUI uncertainty intervalHIC high income countries0302 clinical medicineCost of IllnessLIC low income countriesMedicineUSA United States of AmericaLetter to the EditorMathematical modellingPWID people who inject drugsLiver DiseaseLiver DiseasesVaccinationmathematical modelingGBD Global Burden of DiseaseHepatitis CSVR sustained virologic responseEuropeHCV hepatitis C virusHepatocellular carcinomaHCVGHSS Global Health Sector StrategyRNA Viral030211 gastroenterology & hepatologyAMR region of the AmericasLiver cancerViral hepatitisHumanCarcinoma HepatocellularCoronavirus disease 2019 (COVID-19)EMR Eastern Mediterranean regionViral hepatitis eliminationviral hepatitisContext (language use)World Health OrganizationArticleWHO World Health OrganizationTime-to-Treatment03 medical and health scienceseliminationEnvironmental healthHumansLMIC lower-middle income countriesDisease EradicationDisease burdenHepatitisHepatologySARS-CoV-2business.industryWPR Western Pacific regionCOVID-19Models Theoreticalmedicine.diseaseCost of Illne030104 developmental biologySpainHCC hepatocellular carcinomabusinessJournal of hepatology
researchProduct

Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients

2021

COVID-19 is a current global threat, and the characterization of antibody response is vitally important to update vaccine development and strategies. In this study we assessed SARS-CoV-2 antibody concentrations in SARS-CoV-2 positive patients (N = 272) and subjects vaccinated with the BNT162b2 m-RNA COVID-19 vaccine (N = 1256). For each participant, socio-demographic data, COVID-19 vaccination records, serological analyses, and SARS-CoV-2 infection status were collected. IgG antibodies against S1/S2 antigens of SARS-CoV-2 were detected. Almost all vaccinated subjects (99.8%) showed a seropositivity to anti-SARS-COV-2 IgG and more than 80% of vaccinated subjects had IgG concentrations &gt

0301 basic medicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)virusesImmunologyArticleSerologyPersistence (computer science)03 medical and health sciences0302 clinical medicineAntigenDrug DiscoveryMedicinePharmacology (medical)030212 general & internal medicineskin and connective tissue diseasesPharmacologyantibody concentrations.biologybusiness.industryImmunogenicitySARS-CoV-2 infectionfungiRantibody concentrationsrespiratory tract diseasesVaccinationbody regions030104 developmental biologyInfectious DiseasesImmunizationImmunologybiology.proteinMedicineAntibodybusinessCOVID-19 vaccineVaccines
researchProduct

Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning.

2021

Coronavirus disease 2019 (COVID-19) is a major threat worldwide due to its fast spreading. As yet, there are no established drugs available. Speeding up drug discovery is urgently required. We applied a workflow of combined in silico methods (virtual drug screening, molecular docking and supervised machine learning algorithms) to identify novel drug candidates against COVID-19. We constructed chemical libraries consisting of FDA-approved drugs for drug repositioning and of natural compound datasets from literature mining and the ZINC database to select compounds interacting with SARS-CoV-2 target proteins (spike protein, nucleocapsid protein, and 2′-o-ribose methyltransferase). Supported by…

0301 basic medicineSimeprevirArtificial intelligencevirusesMERS Middle East Respiratory SyndromeHealth InformaticsBiologyMachine learningcomputer.software_genremedicine.disease_causeAntiviral AgentsArticleWHO World Health OrganizationAUC area under the curve03 medical and health sciences0302 clinical medicinessRNA single-stranded RNA virusmedicineChemotherapyHumansSARS severe acute respiratory syndromeCOVID-19 coronavirus disease 2019CoronavirusNatural productsVirtual screeningACE2 angiotensin converting enzyme 2Drug discoverybusiness.industrySARS-CoV-2COVID-19LBE lowest binding energyFDA Food and Drug AdministrationROC receiver operating characteristicComputer Science ApplicationsHIV human immunodeficiency virusMolecular Docking SimulationDrug repositioning030104 developmental biologyDrug developmentSevere acute respiratory syndrome-related coronavirusParitaprevirInfectious diseasesRespiratory virusArtificial intelligenceSupervised Machine Learningbusinesscomputer030217 neurology & neurosurgeryComputers in biology and medicine
researchProduct

Screening of potent phytochemical inhibitors against SARS-CoV-2 protease and its two Asian mutants

2021

Abstract Background COVID-19, declared a pandemic in March 2020 by the World Health Organization is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The virus has already killed more than 2.3 million people worldwide. Object The principal intent of this work was to investigate lead compounds by screening natural product library (NPASS) for possible treatment of COVID-19. Methods Pharmacophore features were used to screen a large database to get a small dataset for structure-based virtual screening of natural product compounds. In the structure-based screening, molecular docking was performed to find a potent inhibitor molecule against the main protease (Mpro) of SARS-…

0301 basic medicineStereochemistrymedicine.medical_treatmentPhytochemicalsProtein Data Bank (RCSB PDB)Health Informaticsmedicine.disease_causeMolecular Docking SimulationAntiviral AgentsArticleDocking03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineHumansProtease InhibitorsCoronavirusVirtual screeningNatural productsProteaseChemistrySARS-CoV-2COVID-19Computer Science ApplicationsProteaseCoronavirusMolecular Docking Simulation030104 developmental biologyDocking (molecular)PharmacophoreLead compound030217 neurology & neurosurgeryMproPeptide HydrolasesComputers in Biology and Medicine
researchProduct

COVID 19-Induced Smell and Taste Impairments: Putative Impact on Physiology

2021

This article is part of the Research Topic "The Tribute of Physiology for the Understanding of COVID-19 Disease".; International audience; Smell and taste impairments are recognized as common symptoms in COVID 19 patients even in an asymptomatic phase. Indeed, depending on the country, in up to 85-90% of cases anosmia and dysgeusia are reported. We will review briefly the main mechanisms involved in the physiology of olfaction and taste focusing on receptors and transduction as well as the main neuroanatomical pathways. Then we will examine the current evidences, even if still fragmented and unsystematic, explaining the disturbances and mode of action of the virus at the level of the nasal …

0301 basic medicineTaste2019-20 coronavirus outbreakFood intakeCoronavirus disease 2019 (COVID-19)[SDV.MHEP.PHY] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]PhysiologyAnosmiaPhysiologyfeeding behaviorOlfactionReviewlcsh:Physiologytaste03 medical and health sciences0302 clinical medicinePhysiology (medical)[SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]medicinesmelllcsh:QP1-981business.industryCOVID-193. Good healthDysgeusia[SDV.AEN] Life Sciences [q-bio]/Food and Nutrition030104 developmental biologymedicine.symptomphysiopathologybusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionTransduction (physiology)COVID 19030217 neurology & neurosurgeryFrontiers in Physiology
researchProduct

Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.

2020

AbstractCoronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct…

0301 basic medicinecoronavirusAnti-Inflammatory AgentsReview Article030204 cardiovascular system & hematologymedicine.disease_causelaw.inventioncovid190302 clinical medicineRandomized controlled triallawAntithromboticPandemicViralanticoagulationCoronavirusGlycosaminoglycansAnimals; Anti-Inflammatory Agents; Anticoagulants; Antiviral Agents; Betacoronavirus; Coronavirus Infections; Fibrinolytic Agents; Glycosaminoglycans; Hemostasis; Humans; Inflammation; Pandemics; Platelet Aggregation Inhibitors; Pneumonia Viral; Thrombosiscoronavirus 2immunomodulatorHematologyHeparinThrombosisantithrombinCoronavirus Infectionsmedicine.drugmedicine.medical_specialtyPneumonia Viralcoronavirus disease 2019 thrombosis inflammation fibrinolytic therapy anticoagulation immunomodulator antithrombin thrombomodulinAntiviral Agents03 medical and health sciencescoronavirus disease 2019BetacoronavirusFibrinolytic AgentsmedicineAnimalsHumansthrombosis COVID-19 coronavirusDosingIntensive care medicinePandemicsthrombosisInflammationHemostasisbusiness.industrySARS-CoV-2AnticoagulantsCOVID-19ThrombosisPneumoniathrombomodulinmedicine.diseaseReview articleCOVID-19 Drug Treatment030104 developmental biologyinflammationfibrinolytic therapybusinessPlatelet Aggregation InhibitorsThrombosis and haemostasis
researchProduct

Mortality in COVID-19 disease patients: Correlating Association of Major histocompatibility complex (MHC) with severe acute respiratory syndrome 2 (S…

2020

Highlights • In addition to ethnicity, socio-economic factors, prior vaccinations and exposure to other coronaviruses, other factors need to be considered to explain geographical and regional variations in susceptibility, severity of clinical expression of COVID-19 disease and outcomes. • Differences in peptide binding of SARS-CoV-2 variants to MHC class II, but not to MHC class I alleles frequent in individuals with African, Asian or Caucasian descent could be identified. • Single mutations in the wildtype of SARS-CoV-2, the so called B strain or L strain impact on MHC presentation • Most likely there is selective pressure from MHC class II alleles in regard to binding of the ORF8 (L84S) v…

0301 basic medicinecross-reactivityMHC bindingPeptide bindingmedicine.disease_causeAutoimmunity0302 clinical medicine030212 general & internal medicineMutationepitopeautoimmunityGeneral MedicineHLAEuropeviral variantsInfectious DiseasesCoronavirus InfectionsPeptides ; COVID-19 ; Disease association ; Cross-reactivity ; MHC ; T-cells ; Autoimmunity ; Epitope ; Cytokines ; Viral variants ; HLA ; SARS ; SARS-CoV-2 ; MHC bindingMicrobiology (medical)Asia030106 microbiologyPneumonia ViralHuman leukocyte antigenBiologyMajor histocompatibility complexArticlelcsh:Infectious and parasitic diseases03 medical and health sciencesBetacoronavirusMHC class ImedicineHumanslcsh:RC109-216AllelePandemicsAllelesSARSMHC class IISARS-CoV-2T-cellsdisease associationHistocompatibility Antigens Class IHistocompatibility Antigens Class IICOVID-19cytokinesImmunologyAfricabiology.proteinpeptidesMHCInternational Journal of Infectious Diseases
researchProduct

Characteristics and Outcomes of 35 Breast Cancer Patients Infected With COVID-19

2020

Since December 2019, a novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly engulfed the world. Cancer patients infected with COVID-19 are considered to carry higher severity of the disease and higher mortality rate than common COVID-19 patients in previous studies. However, due to the poor clinical information on COVID-19 patients with cancer, the evidences that supported this conclusion are insufficient. At present, rather limited reports have analyzed the clinical data of breast cancer patients infected with COVID-19. Therefore, in this retrospective study, we described the clinical characteristics and the outcomes of 35 …

0301 basic medicinemedicine.medical_specialtyCancer ResearchCoronavirus disease 2019 (COVID-19)Diseasemedicine.disease_causelcsh:RC254-282Asymptomatic03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerInternal medicineMedicineclinical characteristicsCoronavirusOriginal Researchnon-cancerbusiness.industrySARS-CoV-2Mortality rateCancerRetrospective cohort studylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisprognosismedicine.symptombusinessFrontiers in Oncology
researchProduct

Managing cancer patients during the COVID-19 pandemic:an ESMO multidisciplinary expert consensus

2020

We established an international consortium to review and discuss relevant clinical evidence in order to develop expert consensus statements related to cancer management during the severe acute respiratory syndrome coronavirus 2-related disease (COVID-19) pandemic. The steering committee prepared 10 working packages addressing significant clinical questions from diagnosis to surgery. During a virtual consensus meeting of 62 global experts and one patient advocate, led by the European Society for Medical Oncology, statements were discussed, amended and voted upon. When consensus could not be reached, the panel revised statements until a consensus was reached. Overall, the expert panel agreed …

0301 basic medicinemedicine.medical_specialtyConsensusCoronavirus disease 2019 (COVID-19)Settore MED/18 - CHIRURGIA GENERALEPneumonia ViraleducationDiseaseMedical OncologyReal-Time Polymerase Chain ReactionSpecial Article03 medical and health sciencesBetacoronavirus0302 clinical medicineMultidisciplinary approachNeoplasmsPandemicGranulocyte Colony-Stimulating FactorMedicineHumansDisease management (health)PandemicsSocieties Medicalbusiness.industrySARS-CoV-2Expert consensusCOVID-19Disease ManagementcovidHematologyTelemedicineEurope030104 developmental biologyOncology030220 oncology & carcinogenesisFamily medicineCancer managementSevere acute respiratory syndrome coronavirusbusinessCoronavirus InfectionsT-Lymphocytes Cytotoxic
researchProduct